Literature DB >> 11430546

Effects of inhalation of perfluorocarbon aerosol on oxygenation and pulmonary function compared to PGI2 inhalation in a sheep model of oleic acid-induced lung injury.

M Ragaller1, J Bleyl, U Tschö, T Winkler, M Regner, S Rasche, T Koch, M Albrecht.   

Abstract

OBJECTIVE: To evaluate the effects of PFC aerosol compared to PGI2 aerosol and NaCl aerosol on gas exchange and lung mechanics in oleic acid-induced acute lung injury.
DESIGN: A prospective, controlled, randomised, in vivo animal laboratory study.
SETTING: Research laboratory at an university hospital.
SUBJECTS: Twenty one (n = 21) adult sheep of either gender weighing 26.8+/-6.4 kg.
INTERVENTIONS: The animals were randomised to three groups: PFC aerosol (perfluorooctane), PFC group; prostacyclin aerosol (Flolan), PGI2 group; and NaCl aerosol (0.9% sodium chloride solution), control group. After induction of anaesthesia and placement of vascular catheters, lung injury was induced with 0.12 ml x kg(-1) oleic acid. Aerosols were continuously administered for 2 h using a jet nebuliser. Gas exchange, pulmonary mechanic, and haemodynamic parameters were obtained at regular intervals.
MEASUREMENTS AND MAIN RESULTS: PFC aerosol increased oxygenation (PaO2) 15 min after the initiation of treatment up to 120 min (P < 0.05). Transpulmonary shunt improved in the PFC group (P < 0.05) while it did not change in the two other groups. PFC aerosol reduced maximum airway pressure (Pmax) (median) significantly from (median) 38 mbar to 32 mbar (P < 0.05). Static compliance improved significantly in the PFC group (P < 0.05).
CONCLUSION: The inhalation of a PFC aerosol led to a significant improvement in pulmonary mechanics and gas exchange, which was not observed in the other two groups. These data suggest that a small dose of perfluorocarbon will have beneficial effects on gas exchange and respiratory mechanics. Therefore, the non-invasive aerosol application technique seems to be a reasonable alternative to administer perfluorocarbons in severe lung injury.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11430546     DOI: 10.1007/s001340100921

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  6 in total

1.  Effects of vaporized perfluorohexane and partial liquid ventilation on regional distribution of alveolar damage in experimental lung injury.

Authors:  Peter M Spieth; Lilla Knels; Michael Kasper; André Domingues Quelhas; Bärbel Wiedemann; Amelie Lupp; Matthias Hübler; Antonio Giannella Neto; Antonio Gianella Neto; Thea Koch; Marcelo Gama de Abreu
Journal:  Intensive Care Med       Date:  2006-11-08       Impact factor: 17.440

Review 2.  Administration of Drugs/Gene Products to the Respiratory System: A Historical Perspective of the Use of Inert Liquids.

Authors:  Deepthi Alapati; Thomas H Shaffer
Journal:  Front Physiol       Date:  2022-05-10       Impact factor: 4.755

3.  Acute lung injury and acute respiratory distress syndrome.

Authors:  Maximillian Ragaller; Torsten Richter
Journal:  J Emerg Trauma Shock       Date:  2010-01

4.  [Reduction in the aggressiveness of ventilation by inhalation of perfluorohexane after therapy of oleic acid-induced respiratory failure].

Authors:  J-U Bleyl; U Tschö; M Regner; O Vicent; M Hübler; M G de Abreu; T Koch; D M Albrecht; M Ragaller
Journal:  Anaesthesist       Date:  2004-02       Impact factor: 1.041

5.  Inhalation of nebulized perfluorochemical enhances recombinant adenovirus and adeno-associated virus-mediated gene expression in lung epithelium.

Authors:  Travis Beckett; Laura Bonneau; Alan Howard; James Blanchard; Juan Borda; Daniel J Weiner; Lili Wang; Guang Ping Gao; Jay K Kolls; Rudolf Bohm; Denny Liggitt; Daniel J Weiss
Journal:  Hum Gene Ther Methods       Date:  2012-05-08       Impact factor: 2.396

6.  Electrical impedance tomography (EIT) for quantification of pulmonary edema in acute lung injury.

Authors:  Constantin J C Trepte; Charles R Phillips; Josep Solà; Andy Adler; Sebastian A Haas; Michael Rapin; Stephan H Böhm; Daniel A Reuter
Journal:  Crit Care       Date:  2016-01-22       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.